AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers.
Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.
“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship.”
Jacob Van Naarden, President of Lilly Oncology, added, “Partnering with AdvanCell aligns with our commitment to advancing innovative radiopharmaceuticals. We are excited to explore the potential of Pb-212-based alpha therapies as we work to bring meaningful new treatments for patients.”
Financial terms of the agreement were not disclosed.
About AdvanCell
AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210990350/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KRAFTON Records All Time Highs in Sales (2.7098T KRW) and Operating Profit (1.1825T KRW) in 202411.2.2025 08:00:00 CET | Press release
Record-breaking earnings, with an average annual growth rate of sales reaching 20% over the past five yearsAims to hit 7T KRW in sales and double the corporate value by ‘securing a Big Franchise IP’Enhancing innovation in the global gaming industry via AI technology advancements KRAFTON, Inc. held an Investor Relations (IR) briefing on February 11, announcing its financial results for the fourth quarter and full year of 2024. According to consolidated financial statements under Korean International Financial Reporting Standards (K-IFRS), KRAFTON recorded 2.7098T KRW and operating profit (OP) of 1.1825T KRW for 2024, marking new all-time highs. These figures represent year-over-year (YoY) growth of 41.8% in sales and 54.0% in OP, driven by the continued expansion and sustainability of the PUBG IP, resulting in an average annual sales growth rate of 20% over the past five years. In the fourth quarter of 2024, KRAFTON recorded 617.6B KRW in sales and 215.5B KRW in OP, reflecting YoY incre
MammaPrint® Reimbursement Indication Extended in Belgium11.2.2025 08:00:00 CET | Press release
Agendia®, Inc. announced today that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) located in Brussels has expanded the reimbursement indication for MammaPrint® to include its use in the neoadjuvant setting, effective January 1, 2025. The genomic assay will now be available for full reimbursement for patients with HR+/HER2 negative early-stage breast cancer in both the pre- and postoperative settings, enabling testing on core needle biopsies for neoadjuvant treatment decisions—a pivotal advancement in providing patients with the personalized care they require. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210842892/en/ (Graphic: Business Wire) "The ability to now use MammaPrint on core needle biopsy specimen in Belgium represents a significant step for personalized treatment for women battling breast cancer," said Professor Martine Piccart, Honorary Professor of Oncology at the Université Libr
EH Group Achieves ISO 9001 Certification11.2.2025 08:00:00 CET | Press release
EH Group is proud to announce that we have secured ISO 9001 granted by leading global certification body SQS. Their rigorous audit process confirmed that our development and production processes meet the highest international standard for quality management. The implementation of this standard highlights our focus on quality and continuous improvement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210743927/en/ EH FUEL CELLS receive ISO 9001 (Graphic: Business Wire) Standards “Preparing for ISO 9001 certification has meant involving the entire team, and going to the core of our technology development and production processes. Achieving it demonstrates that we have established robust and well-defined procedures across all our business activities,” states Danny Knippen, Safety, Reliability & Certification Engineer. “The ISO 9001 certification is an important milestone for the company and shows our commitment to delivering
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion11.2.2025 07:17:00 CET | Press release
Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safetyCulminates growth journey as part of Blackstone Life Sciences Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that the company has entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor that originated at Novartis, being developed to prevent stroke and systemic embolism in patients with atrial fibrillation as well as to prevent the recurrence of blood clots in patients with cancer. This press release fea
24,000 Registered Attendees Fill the Halls of Successful SPIE Photonics West 202510.2.2025 20:55:00 CET | Press release
The largest annual optics and photonics event of the year highlighted exciting new research, networking, and the latest in photonics products and industry trends SPIE, the international society for optics and photonics, registered 24,000 optics and photonics professionals from over 75countries for Photonics West, as the Society hosted the largest international annual photonics meeting at San Francisco’s Moscone Center. The dynamic week, which ran from 25 to 30 January, featured 1,588 exhibitors and 5,000 technical presentations across four focused tracks – BiOS, LASE, OPTO, Quantum West – four exhibitions, and the co-located AR | VR | MR conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210056991/en/ SPIE Photonics West 2025 exhibition opens for business at San Francisco's Moscone Center. (Photo: Business Wire) “Photonics West marks the start of the optics and photonics calendar every year,” said SPIE CEO Kent Ro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom